U.S. markets close in 4 hours 45 minutes

Shionogi & Co., Ltd. (4507.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
Add to watchlist
5,727.00+51.00 (+0.90%)
At close: 3:15PM JST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5,676.00
Bid5,724.00 x 0
Ask5,729.00 x 0
Day's Range5,634.00 - 5,729.00
52 Week Range4,761.00 - 7,183.00
Avg. Volume1,014,822
Market Cap1.726T
Beta (5Y Monthly)0.88
PE Ratio (TTM)14.97
EPS (TTM)382.67
Earnings DateMay 10, 2021
Forward Dividend & Yield106.00 (1.87%)
Ex-Dividend DateMar 30, 2021
1y Target Est7,875.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      Japan, eyeing Olympics, lines up half-billion doses of COVID-19 vaccine

      Japan is making an aggressive move to grab enough coronavirus vaccine to inoculate its population four times over, a push the government hopes will instil confidence that it can host a delayed summer Olympics next year. Like other rich countries, Japan is signing multiple deals because some of the vaccines could fail in clinical trials or require more than one dose, an approach some experts consider prudent. Chief Cabinet Secretary Yoshihide Suga, the top government spokesman, said Japan was working with Olympic organisers on how to go ahead with the Games, tying the effort to the need to secure a vaccine.

    • Reuters

      CORRECTED-(OFFICIAL)-GSK says long-acting HIV prevention drug 66% more effective than Truvada

      Britain's GSK said on Tuesday that an injection of its cabotegravir drug given every two months was found to be 66% more effective in preventing HIV infections than Gilead's Truvada daily oral pills. HIV incidence rate - or the number of people who contract the infection in a period - was 0.41% with the injection, compared with 1.22% with Gilead's Truvada, final data from a study presented at the virtual AIDS conference showed. Truvada is currently the standard of care for preventing HIV, but GSK hopes to challenge its dominance by making shorter, long-lasting regimens and less toxic alternatives through its ViiV Healthcare unit.

    • Reuters

      U.S. FDA approves GSK unit's drug to treat infants and children with HIV

      The U.S. Food and Drug Administration has approved a drug to treat infants and children with HIV, with the drug having been developed by drugmaker GlaxoSmithKline's HIV drugs division ViiV Healthcare, the FDA and the GSK unit said. The FDA said on Friday it was granting Viiv the approval of Tivicay and Tivicay PD tablets "for suspension to treat HIV-1 infection in pediatric patients at least four weeks old and weighing at least 3 kgs in combination with other antiretroviral treatments". The drug is currently under review by the European Medicines Agency, ViiV, in which Pfizer and Shionogi have small stakes, said in a separate statement.